Acorda Announces Departure of Michael Rogers

ARDSLEY, N.Y.–(BUSINESS WIRE)– Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that Chief
Financial Officer Michael Rogers has left the company. David Lawrence,
Acorda’s Chief of Business Operations, has assumed the role of Chief,
Business Operations and Principal Accounting Officer. Andrew Hindman,
Acorda’s Chief Business Development Officer, has assumed responsibility
for Financial Planning and Analysis and Investor Relations. Mr. Rogers
will serve as a consultant to the Company through the end of the year as
part of this transition.

“We thank Mike for his many contributions to Acorda during his tenure.
He was a key part of the team responsible for the acquisitions of
Civitas and Biotie, which have helped position Acorda as a leader in
Parkinson’s disease therapeutic development,” said Ron Cohen, M.D.,
President and CEO of Acorda Therapeutics. “Mike has been commuting from
Boston throughout his years at Acorda, which has been challenging for
him and his family. I’m grateful for his dedication to the Company
during this time.”

“I also want to thank Dave Lawrence and Andrew Hindman for taking on
additional responsibilities within the Company. Dave led our accounting
and finance teams for many years, and Andrew has a strong financial
background and long-standing relationships with many of Acorda’s
investors.”

About Acorda Therapeutics

Founded in 1995, Acorda
Therapeutics is a biotechnology company focused on developing
therapies that restore function and improve the lives of people with
neurological disorders.

Acorda has a pipeline of novel neurological therapies addressing a range
of disorders, including Parkinson’s disease, post-stroke walking
difficulties, migraine, and multiple sclerosis. Acorda markets
three FDA-approved therapies, including AMPYRA^® (dalfampridine)
Extended Release Tablets, 10 mg.

For more information, please visit the Company’s website at: www.acorda.com.

Forward-Looking Statement

This press release includes forward-looking statements. All statements,
other than statements of historical facts, regarding management’s
expectations, beliefs, goals, plans or prospects should be considered
forward-looking. These statements are subject to risks and uncertainties
that could cause actual results to differ materially, including: the
ability to complete the Biotie transaction on a timely basis; the
ability to realize the benefits anticipated from the Biotie and Civitas
transactions, among other reasons because acquired development programs
are generally subject to all the risks inherent in the drug development
process and our knowledge of the risks specifically relevant to acquired
programs generally improves over time; the ability to successfully
integrate Biotie’s operations and Civitas’ operations, respectively,
into our operations; we may need to raise additional funds to finance
our expanded operations and may not be able to do so on acceptable
terms; our ability to successfully market and sell
Ampyra (dalfampridine) Extended Release Tablets, 10 mg in the U.S.;
third party payers (including governmental agencies) may not reimburse
for the use of Ampyra or our other products at acceptable rates or at
all and may impose restrictive prior authorization requirements that
limit or block prescriptions; the risk of unfavorable results from
future studies of Ampyra or from our other research and development
programs, including CVT-301 or any other acquired or in-licensed
programs; we may not be able to complete development of, obtain
regulatory approval for, or successfully market CVT-301, any other
products under development, or the products that we will acquire when we
complete the Biotie transaction; the occurrence of adverse safety events
with our products; delays in obtaining or failure to obtain and maintain
regulatory approval of or to successfully market Fampyra outside of the
U.S. and our dependence on our collaborator Biogen in connection
therewith; competition; failure to protect our intellectual property, to
defend against the intellectual property claims of others or to obtain
third party intellectual property licenses needed for the
commercialization of our products; and failure to comply with regulatory
requirements could result in adverse action by regulatory agencies.

These and other risks are described in greater detail in our filings
with the Securities and Exchange Commission. We may not actually achieve
the goals or plans described in our forward-looking statements, and
investors should not place undue reliance on these statements.
Forward-looking statements made in this presentation are made only as of
the date hereof, and we disclaim any intent or obligation to update any
forward-looking statements as a result of developments occurring after
the date of this presentation.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161004005521/en/